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We thank Dr Guazzi for his comments. The number of patients studied was based on the results observed in a previous study on the interaction between aspirin and enalapril. 1 The imbalance between groups was mainly due to the exclusion of patients with baseline pulmonary capillary wedge pressures Ͻ15 mm Hg. Nevertheless, baseline characteristics and hemodynamics were similar in both groups.
Although the noninvasive monitoring of blood pressure by a cuff and mercury column sphygmotonometer is an old and simple method, it remains validated and extensively used in studies on the effects of drugs on systemic vascular resistance. 1 Three consecutive measures were performed at each point, and the mean value was used for data collection. Because the study was double-blinded, the random zero method was considered unnecessary.
Dr Guazzi misinterprets both the results of our trial and previous studies. We clearly demonstrated that enalapril reduces systemic vascular resistance more effectively when given in combination with ticlopidine than with aspirin. Hall et al, 1 and even Guazzi himself, 2 also demonstrated a negative aspirinenalapril interaction on mean arterial pressure decrease. These similar reductions in total pulmonary resistance when enalapril is administered in combination with aspirin or ticlopidine suggests that ACE inhibitors reduce pulmonary artery pressure by prostaglandin-independent mechanisms, such as a decrease in angiotensin II or norepinephrine 3 or a bradykinin-induced increase in endothelin-derived nitric oxide. 4 Indeed, Hall et al 1 also noted a reduction, although nonsignificant, in pulmonary mean artery pressure when enalapril was given with or after aspirin; this reduction was attributed to a lack of interaction between aspirin and enalapril in the pulmonary vessels. 1 A large-scale study seemed difficult to devise and perform because hemodynamic measurements with continuous right heart catheterization during 4 hours were required. No placebo group or crossover design was planned because the purpose of our study was not to duplicate established findings on ACE inhibitors and aspirin interaction 1,2 but to compare aspirin and ticlopidine when given with ACE inhibitors. Our sample size was chosen to study hemodynamic interactions. We clearly demonstrated that ticlopidine has no interaction with enalapril, in contrast to aspirin, which attenuates the systemic vasodilator effect of enalapril. However, definite conclusions on the clinical implications of our study would require a large, multicenter, clinical trial.
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